z-logo
Premium
Myocardial infarction quantification with Manganese‐Enhanced MRI (MEMRI) in mice using a 3T clinical scanner
Author(s) -
Delattre Bénédicte M. A.,
Braunersreuther Vincent,
Hyacinthe JeanNoël,
Crowe Lindsey A.,
Mach François,
Vallée JeanPaul
Publication year - 2010
Publication title -
nmr in biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 114
eISSN - 1099-1492
pISSN - 0952-3480
DOI - 10.1002/nbm.1489
Subject(s) - myocardial infarction , infarction , medicine , cardiology , ejection fraction , gold standard (test) , coronary occlusion , nuclear medicine , heart failure
Manganese (Mn 2+ ) was recognized early as an efficient intracellular MR contrast agent to assess cardiomyocyte viability. It had previously been used for the assessment of myocardial infarction in various animal models from pig to mouse. However, whether Manganese‐Enhanced MRI (MEMRI) is also able to assess infarction in the acute phase of a coronary occlusion reperfusion model in mice has not yet been demonstrated. This model is of particular interest as it is closer to the situation encountered in the clinical setting. This study aimed to measure infarction volume taking TTC staining as a gold standard, as well as global and regional function before and after Mn 2+ injection using a clinical 3T scanner. The first step of this study was to perform a dose‐response curve in order to optimize the injection protocol. Infarction volume measured with MEMRI was strongly correlated to TTC staining. Ejection fraction (EF) and percent wall thickening measurements allowed evaluation of global and regional function. While EF must be measured before Mn 2+ injection to avoid bias introduced by the reduction of contrast in cine images, percent wall thickening can be measured either before or after Mn 2+ injection and depicts accurately infarct related contraction deficit. This study is the first step for further longitudinal studies of cardiac disease in mice on a clinical 3T scanner, a widely available platform. Copyright © 2010 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here